Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance

Bristol-Myers Squibb CoTrade
Direxion Daily Semiconductor Bear 3X SharesTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B), while Direxion Daily Semiconductor Bear 3X Shares trades at $41.01. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.

BMYSOXS
Market Cap
$129.94B
Sector
HealthLeveraged / Inverse
52-Week High
$65.89$1.49K
52-Week Low
$42.60$32.50
Enterprise Value
$163.92B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

Direxion Daily Semiconductor Bear 3X Shares

SOXS, the Direxion Daily Semiconductor Bear 3X ETF, is trading at $40.97, down 9.38% today amid volatile semiconductor sector conditions. The technical picture remains bearish with moving averages signaling continued downward pressure, though oversold RSI levels suggest potential for near-term bounce. Recent news highlights SOXS benefiting from AI-fueled tech rally concerns and semiconductor stock sell-offs, with the fund executing a 1:10 stock split effective July 26, 2026.

As a leveraged inverse ETF, SOXS offers amplified exposure to semiconductor sector declines but carries significant decay and volatility risks. The fund's performance is heavily dependent on continued semiconductor weakness, which faces fundamental challenges from AI infrastructure growth and memory chip competition. Investors should understand the complex nature of inverse leveraged products before considering positions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Direxion Daily Semiconductor Bear 3X Shares

SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.

Read more on SOXS